Litcius/Paper detail

Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial

Fred Saad, Antoine Thiery-Vuillemin, Paweł Wiechno, B. Yа. Alekseev, Núria Sala, Robert H. Jones, Ivo Kocák, Vincenzo Emanuele Chiurì, Jacek Jassem, Aude Fléchon, Charles H. Redfern, Jinyu Kang, Joseph E. Burgents, Christopher Gresty, Arnold Degboe, Noel W. Clarke

2022The Lancet Oncology30 citationsDOI

Topics & Concepts

MedicineProstate cancerClinical endpointInternal medicinePlaceboAbiraterone acetateDocetaxelAndrogen deprivation therapyOncologyEnzalutamidePrednisoneUrologyRandomized controlled trialCancerPathologyAndrogen receptorAlternative medicineProstate Cancer Treatment and ResearchProstate Cancer Diagnosis and TreatmentAdvanced Breast Cancer Therapies
Patient-reported outcomes with olaparib plus abiraterone versus placebo plus abiraterone for metastatic castration-resistant prostate cancer: a randomised, double-blind, phase 2 trial | Litcius